Lipella Pharmaceuticals Inc. (LIPO)
OTC PINK OTC PINK Primary Summary
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 4, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
Listen: PITTSBURGH, April 22, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.
Lipella Pharmaceuticals Inc. (LIPO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lipella Pharmaceuticals Inc. ever had a stock split?
Lipella Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jonathan Kaufman CEO | OTC PINK Exchange | 53630L100 CUSIP |
| US Country | 5 Employees | - Last Dividend | 8 Nov 2024 Last Split | 19 Dec 2022 IPO Date |
Overview
Lipella Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative drug formulations. The company implements a strategy of reformulating the active ingredients in generic drugs to create optimized versions for various medical applications. Established in 2005, Lipella Pharmaceuticals has its headquarters in Pittsburgh, Pennsylvania. The company's research and development focus is primarily geared towards providing solutions for conditions that are currently underserved by the pharmaceutical market. Through its commitment to innovation and patient care, Lipella Pharmaceuticals strives to address the needs of patients suffering from specific medical conditions by leveraging existing pharmacological knowledge and applying it in novel ways.
Products and Services
Lipella Pharmaceuticals Inc. has several key products in its pipeline, each targeting different medical conditions using reformulated versions of the drug tacrolimus. The products are in various stages of clinical trials, demonstrating the company's commitment to advancing medical research and providing new treatment options.
- LP-10: A reformulation of tacrolimus designed for patients suffering from radiation-induced hemorrhagic cystitis. This condition can arise as a complication of radiation therapy, and LP-10 has reached a promising stage of development with the completion of a Phase 2a clinical trial. The aim is to offer an effective treatment for managing the symptoms and providing relief to patients affected by this painful and debilitating condition.
- LP-310: This product represents another innovative use of tacrolimus, reformulated for the treatment of oral lichen planus — a chronic inflammatory condition that affects the mucous membranes of the mouth. LP-310 is in development to provide a targeted therapeutic option for patients dealing with the discomfort and potential complications of oral lichen planus, indicating the company's focus on addressing less common but impactful diseases.
- LP-410: An oral liposomal formulation of tacrolimus, LP-410 is under development for the treatment of oral graft-versus-host disease (GVHD). GVHD can occur after a stem cell or bone marrow transplant when the donated cells attack the recipient's body. By reformulating tacrolimus into a liposomal delivery system designed for oral administration, LP-410 aims to offer a novel and effective treatment option for managing this serious and often life-threatening condition.
